ReviewEndocrine2020
Diagnosis and management of hypocalcemia.
Review in Endocrine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.
- The association between hypoparathyroidism and cognitive impairment: a systematic review.Journal of endocrinological investigation · 2021Pooled it
- Parathyroid autotransplantation into the brachioradialis protects parathyroid function during total thyroidectomy.Frontiers in endocrinology · 2026Trial
- Are Routine Labs Necessary? Postoperative Electrolyte Trends in Lipedema Patients Undergoing Liposuction: Insights from a Single-Center Retrospective Cohort.Aesthetic plastic surgery · 2026Article
- Hypocalcaemic cardiomyopathy with recurrent heart failure: a natural rechallenge case report with 30-month follow-up.European heart journal. Case reports · 2026Article
- Long-term effects of carbamazepine on bone-related biochemical markers in patients with epilepsy.Acta epileptologica · 2026Article
- Acute severe hyperphosphatemia and secondary hypocalcemia after phosphate enema administration in a constipated post-trauma patient recovering from pelvic surgery: a case report.Journal of surgical case reports · 2026Article
- Premature Skeletal Aging and Immunological Recovery in Romanian PLWH: A Cross-Sectional Analysis of Gender-Specific and Metabolic Risk Factors.International journal of molecular sciences · 2026Article
- Proton pump inhibitor induced hypocalcemia presenting with carpopedal spasm- a rare case report from Nepal.International journal of emergency medicine · 2026Article
- Case report of severe hypocalcemia with atypical symptoms after zoledronic acid in palliative care: a deprescribing pitfall.BMC palliative care · 2026Article
- Adjustment of total plasma calcium for albumin concentrations avoids overdiagnosis of hypocalcemia in geriatric patients.Zeitschrift fur Gerontologie und Geriatrie · 2026Article
- Fatal West Nile Encephalomyelitis in a Young Woman with Hypoparathyroidism and Sjögren's Syndrome. Molecular Insights into Viral Neuro-Invasivity.International journal of molecular sciences · 2025Article
- Ethylenediaminetetraacetic acid conjugated with polyethylene glycol is a safe chelator for colonic epithelial denudation and intestinal epithelial replacement therapy.Scientific reports · 2025Article
- Article
- Hypocalcemia-related pustulosis: a case report.Journal of medical case reports · 2025Article
- Hypocalcemia Revisited: Thinking Outside the Box!Cureus · 2025Article
- Bioreactor Systems to Mass-Produce the Undervalued Crop,Engineering in life sciences · 2025Article
- Evaluation of Bone Mineral Density and Related Factors in Romanian HIV-Positive Patients Undergoing Antiretroviral Therapy.Microorganisms · 2025Article
- Cognitive Function in Individuals with Chronic Hypoparathyroidism-A Prospective Observational Study.The Journal of clinical endocrinology and metabolism · 2025Observational
- Bone in Parathyroid Diseases Revisited: Evidence From Epidemiological, Surgical and New Drug Outcomes.Endocrine reviews · 2025Review
- Temporary hypocalcemia induced by cetuximab sarotalocan without hypomagnesemia in a patient with hypoparathyroidism: a novel case report.Journal of pharmaceutical health care and sciences · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this clinical narrative review is to summarize and critically appraise the literature on the differential diagnosis of hypocalcemia and to provide its correct management. Calcium is essential for muscle contraction and neurotransmitter release, but clinical manifestations of hypocalcaemia (serum calcium level <8 mg/dl; 2.12 mmol/L) may involve almost any organ and system and may range from asymptomatic to life-threating conditions. Disorders causing hypocalcemia can be divided into parathyroid hormone (PTH) and non-PTH mediated. The most frequent cause of hypocalcemia is postsurgical hypoparathyroidism, while a more comprehensive search for other causes is needed for appropriate treatment in the non PTH-mediated forms. Intravenous calcium infusion is essential to raise calcium levels and resolve or minimize symptoms in the setting of acute hypocalcemia. Oral calcium and/or vitamin D supplementation is the most frequently used as treatment of chronic hypocalcemia. In hypoparathyroidism, providing the missing hormone with the use of the recombinant human (rh) PTH(1-84) has been recently approved both by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This new therapy has the advantage of being effective for correcting serum calcium levels and significantly reducing the daily requirements of calcium and active vitamin D supplements. However, due to the high cost, a strict selection of candidates to this therapy is necessary. More challenging is the long-term hypocalcemia treatment, due to its associated complications. The development of long-acting recombinant human PTH will probably modify the management of chronic hypoparathyroidism in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.